Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain technically weak despite strong long-term returns, with FIIs raising their stake while mutual fund holdings declined. The stock trades below most key moving averages, keeping near-term momentum subdued despite the positive regulatory development.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.